[go: up one dir, main page]

AU1759501A - Method of treating a viral infection using antagonists of macrophage colony stimulating factor - Google Patents

Method of treating a viral infection using antagonists of macrophage colony stimulating factor

Info

Publication number
AU1759501A
AU1759501A AU17595/01A AU1759501A AU1759501A AU 1759501 A AU1759501 A AU 1759501A AU 17595/01 A AU17595/01 A AU 17595/01A AU 1759501 A AU1759501 A AU 1759501A AU 1759501 A AU1759501 A AU 1759501A
Authority
AU
Australia
Prior art keywords
antagonists
treating
viral infection
stimulating factor
colony stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17595/01A
Inventor
Kathleen A. Clouse-Strebel
Marion F. Gruber
Joseph Kutza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
Government Of United States, Health & Hu, Secretary of, Department of
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of United States, Health & Hu, Secretary of, Department of, US Department of Health and Human Services filed Critical Government Of United States, Health & Hu, Secretary of, Department of
Publication of AU1759501A publication Critical patent/AU1759501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU17595/01A 1999-11-08 2000-11-07 Method of treating a viral infection using antagonists of macrophage colony stimulating factor Abandoned AU1759501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16405799P 1999-11-08 1999-11-08
US60164057 1999-11-08
PCT/US2000/030850 WO2001034177A2 (en) 1999-11-08 2000-11-07 Method of treating a viral infection using antagonists of macrophage colony stimulating factor

Publications (1)

Publication Number Publication Date
AU1759501A true AU1759501A (en) 2001-06-06

Family

ID=22592791

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17595/01A Abandoned AU1759501A (en) 1999-11-08 2000-11-07 Method of treating a viral infection using antagonists of macrophage colony stimulating factor

Country Status (2)

Country Link
AU (1) AU1759501A (en)
WO (1) WO2001034177A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
RU2401277C2 (en) 2004-01-07 2010-10-10 Чирон Корпорейшн Non-mouse anti-m-csf-antibody (versions), preparation and use thereof
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
BR112016029460A2 (en) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc Methods To Treat Rheumatoid Arthritis
EA036261B1 (en) 2014-10-29 2020-10-20 Файв Прайм Терапьютикс, Инк. Combination therapy for cancer
EP3237447B1 (en) 2014-12-22 2020-12-02 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
PT3283527T (en) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc COMBINATION THERAPEUTIC FOR CANCER
JP2020535119A (en) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク Combination therapy of anti-CSF1R and anti-PD-1 antibody for pancreatic cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141290T1 (en) * 1989-02-10 1996-08-15 Cetus Oncology Corp M-CSF MONOCLONAL ANTIBODIES THAT RECOGNIZE A NEUTRALIZING CONFORMATIONAL EPITOPE
WO1993025687A1 (en) * 1992-06-09 1993-12-23 Chiron Corporation Crystallization of m-csf
WO1995024904A1 (en) * 1994-03-16 1995-09-21 Tanox Biosystems, Inc. Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies

Also Published As

Publication number Publication date
WO2001034177A2 (en) 2001-05-17
WO2001034177A3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
AU5032500A (en) Treatment of irregular ventricular contractions
AUPR596301A0 (en) A method of microwave treatment of wood
AU2001294604A1 (en) Improved radiation therapy treatment method
EP1201177A4 (en) Disposable wiping-out implement and production method therefor
AU5439601A (en) Method of controlling a liquefracture handpiece
GB2351661B (en) Novel method of treatment
AUPQ161099A0 (en) Multirate cochlear stimulation strategy and apparatus
SG86377A1 (en) Method of sterilization
AU4429500A (en) Electrode structure for iontophoresis devices and method of producing the same
IL145875A0 (en) Novel method of treatment
AU1759501A (en) Method of treating a viral infection using antagonists of macrophage colony stimulating factor
AU6294000A (en) Method for purifying granulocyte colony stimulating factor
AU2001290061A1 (en) Analogues of human granulocite colony stimulating factor (g-csf)
IL148138A0 (en) Method of treating body insect infestation
GB9930688D0 (en) Novel method of treatment
AU4598400A (en) Method of treatment
AU2382601A (en) Novel method of treatment
AU8038400A (en) Method of treatment of influenza
AU1353901A (en) Method of treating batten disease
AUPP860099A0 (en) Treatment of feeds
AUPQ080999A0 (en) Method of treatment
AUPQ233299A0 (en) Method of treatment
AUPQ320299A0 (en) Method of treatment
AUPQ835900A0 (en) A method of microwave treatment of wood
GB9930696D0 (en) Novel method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase